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Background: Patients with end-stage renal disease who receive kidney transplants have improved survival and quality
of life compared to patients on dialysis. Unfortunately, transplant patients often have a low vitamin D concentration,
which has well-known effects on calcium and bone metabolism. The effect of vitamin D on other indicators of
transplant function, such as glomerular filtration rate and acute rejection, remains unknown.
Methods/design: We will conduct a systematic review of vitamin D status and outcomes after kidney transplantation.
The primary objective is to assess the relationship between vitamin D and graft function using measured glomerular
filtration rate (GFR) or estimated GFR from serum creatinine concentrations. Secondary outcomes will include acute
rejection, chronic allograft nephropathy, proteinuria and graft loss. We will search MEDLINE, EMBASE, AMED and
CINAHL for randomized and observational studies on adult renal transplant patients who received vitamin D
supplementation or had serum vitamin D concentration measured. We will report study quality using the Cochrane
Risk Assessment Tool for randomized controlled trials and the Newcastle–Ottawa Scale for observational studies.
Quality across studies will be assessed using the GRADE approach. If pooling is deemed appropriate, we will perform
meta-analyses using standard techniques for continuous and discrete variables, depending on the outcome. The
results of this review may inform guideline development for vitamin D supplementation in renal transplant patients
and highlight areas for further research.
Systematic review registration: PROSPERO: CRD42013006464.
Keywords: vitamin D, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, calcitriol, kidney transplantation, graft function,
systematic review, protocolBackground
The prevalence of chronic kidney disease has been pro-
gressively increasing over the last two decades, with
40,385 Canadians being treated for end-stage renal disease
in December 2011 [1]. Of these patients, 58% were receiv-
ing dialysis while 42% had a functioning renal transplant
[1]. Studies have shown that patients who have received
a kidney transplant have improved overall survival, less
cardiovascular disease and improved quality of life com-
pared to similar patients on dialysis [2]. Unfortunately,
kidney transplants can still fail due to acute rejection and* Correspondence: dzimmerman@ottawahospital.on.ca
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unless otherwise stated.chronic allograft nephropathy; transplant failure can result
in a threefold greater risk of death compared to patients
with functioning grafts [3,4]. Given the increasing demand
for renal transplants, it is important to identify modifiable
risk factors implicated in graft failure to improve patient
survival and quality of life.
Vitamin D is a steroid hormone involved in the regula-
tion of calcium, phosphorus and bone metabolism. It is
obtained from the diet and sun exposure and requires
two hydroxylation steps for conversion to its physiolo-
gically active form, 1,25-dihydroxyvitamin D (calcitriol)
[5]. The second hydroxylation step is performed by the
enzyme 1α-hydroxylase, which is found predominantly in
the kidney [5]. Many patients with a GFR less than 30 mL/l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion due to hyperphosphatemia-mediated inhibition of
1α-hydroxylase [6].
It is estimated that 17% of patients with chronic kidney
disease have vitamin D insufficiency, which is defined
as a vitamin D concentration between 15 and 30 ng/mL
(40 to 70 nmol/L), and approximately 80% have vitamin
D deficiency (vitamin D concentration <15 ng/mL or
37 nmol/L) [7]. Renal transplant patients are no exception.
Stavroulopoulos et al. measured the vitamin D concentra-
tion for 104 patients within one year of a transplant and
for 140 patients more than one year after a transplant
[8]. They found that 97% and 94% of these patients,
respectively, had vitamin D concentrations below 30 ng/
mL [8]. Possible reasons for this include the intentional
avoidance of sun exposure by patients on immuno-
suppressants and accelerated vitamin D catabolism by
glucocorticoids [8]. Furthermore, there is a reluctance
among physicians to prescribe vitamin D supplements for
fear of precipitating hypercalcemia, hyperphosphatemia
or hypoparathyroidism in patients with chronic kidney
disease [9]. Aside from the general recommendations
for those with chronic kidney disease, there are no specific
guidelines for vitamin D supplementation for renal trans-
plant patients.
Vitamin D deficiency may impact kidney allograft func-
tion, as vitamin D has known renoprotective properties.
Vitamin D negatively regulates the renin-angiotensin-
aldosterone system (RAAS) and has been shown to
reduce RAAS-mediated renal fibrogenesis in a rat
model of obstructive nephropathy [10,11]. Furthermore,
vitamin D supplementation has been shown to decrease
proteinuria in both human and animal models, which is a
recognized risk factor for progressive renal failure. In rats,
1,25-dihydroxyvitamin D supplementation was found to
reduce glomerulosclerosis and albuminuria through its
anti-proliferative effects [12]. In humans, calcitriol and
paricalcitol supplementation in addition to RAAS inhibition
have been associated with significant proteinuria reductions
in the settings of IgA nephropathy and diabetic nephropa-
thy, respectively [13,14]. A significant association between
vitamin D insufficiency and proteinuria has also been
shown for renal transplant recipients; however, a causal
relationship has not been established [15]. Considering
these findings, RAAS inhibition and proteinuria reduction
are two mechanisms by which vitamin D could positively
affect graft function.
The immunomodulatory effects of vitamin D provide
an additional basis for a role in renal transplantation.
Calcitriol receptors are present on various immune cells,
including T cells, B cells, monocytes and antigen-presenting
cells [16]. In T cells, calcitriol suppresses helper T cell
proliferation and differentiation, alters cytokine production
and causes a shift from a pro-inflammatory Th1 responseto a tolerogenic Th2 response [16,17]. Calcitriol also in-
hibits dendritic cell differentiation and maturation into
antigen-presenting cells, which may be protective in
transplantation [17]. In a rat model of chronic allograft
nephropathy, administration of 1,25-dihydroxyvitamin D3
prolonged allograft survival, decreased episodes of acute
rejection, reduced proteinuria and prevented histologic
changes associated with chronic allograft nephropathy [18].
It follows that vitamin D supplementation may reduce
acute rejection and chronic allograft nephropathy in
humans through its interactions with the immune system.
Given the prevalence of vitamin D deficiency in patients
with chronic kidney disease and the possible benefit of
vitamin D in organ transplantation, it is important to




We will conduct a systematic review to determine the
relationship between vitamin D concentration or supple-
mentation and subsequent allograft function in kidney
transplant recipients. The primary outcome will be graft
function determined by the measurement of GFR (e.g.
inulin clearance) or creatinine clearance (timed urine col-
lection) as estimated from serum creatinine concentrations
at different times post-transplantation. Secondary outcomes
will include acute rejection, chronic allograft nephropathy,
proteinuria and graft loss.
Types of studies
In this review, we will include two types of study: (1)
designs that examine the association between serum
25-hydroxyvitamin D or 1,25-dihydroxyvitamin D concen-
tration and our stated primary and secondary outcomes
and (2) designs that examine the effect of vitamin D sup-
plementation on our stated outcome measures. Although
this is the most inclusive approach, we anticipate several
challenges. First, the thresholds used to define inadequate
25-hydroxyvitamin D levels in various studies may differ
from recent guidelines [9]. For the purposes of this review,
we will use thresholds selected by the study authors. Sec-
ond, we anticipate heterogeneity in vitamin D formulation
with some studies providing nutritional vitamin D supple-
ments (e.g. cholecalciferol) and others using active vitamin
D compounds (e.g. calcitriol and paricalcitol). As these
formulations may affect graft function differently, pooling
these results may be inappropriate (see Discussion).
Search strategy
A comprehensive electronic search will be conducted using
MEDLINE, EMBASE, AMED and CINAHL with the assist-
ance of a librarian experienced in systematic reviews. A
structured search strategy will be based on controlled
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prioritize sensitivity (see the Appendix). The references of
included articles and existing reviews will be scanned for
additional resources.
Study screening and inclusion
All titles and abstracts from our comprehensive search
will be screened by two independent reviewers. The
inclusion and exclusion criteria used for each screening
step are outlined below. If no abstract is available, the
full text will be obtained unless the article can be confi-
dently excluded by its title alone. In general, if there is
any doubt as to whether a study should be excluded, the
study will proceed to the full text screen to reduce the
likelihood of incorrectly excluding a relevant study. Full
text copies of potentially relevant papers will be obtained
for independent analysis by two reviewers. Any disagree-
ments will be reconciled by a third party.
Inclusion criteria
Our review will focus on adult male and female subjects
who received either a living donor or deceased donor
kidney transplant. We will include retrospective and pro-
spective studies (cross-sectional, case–control and cohort)
and interventional studies (randomized and non-random-
ized). For studies that measure serum vitamin D concentra-
tion, we have not predefined when a sample needs to be
measured (e.g. pre-transplant, 3-months post-transplant, 1-
year post-transplant, etc.). For studies that assess the impact
of vitamin D supplementation, all doses and formulations
of vitamin D will be included. Studies must report one or
more of the primary or secondary outcomes listed above to
be eligible. Non-English articles will be included when there
is a translator available at our institution. Publication dates
will be restricted to 1990 and later given the changes in im-
munosuppression, transplant outcomes and measurement
techniques for vitamin D that have occurred since then.
Exclusion criteria
We will exclude case reports, narrative reviews, letters,
animal studies and those with a sample size <30. Studies
involving only pediatric patients or combined adult/
pediatric populations where the data are not reported
separately will be excluded. Studies involving multi-organ
transplantation (e.g. kidney-pancreas) will also be excluded.
We will exclude studies that report only bone-specific out-
comes (e.g. fracture rates and bone mineral density), as
there is an existing Cochrane review on this topic [19].
Data extraction
Each study included in the review will undergo a stan-
dardized data extraction process using a pre-formatted
spreadsheet. The extracted data will be verified by a
second reviewer to reduce reviewer errors and bias.Information pertaining to study identification (first author,
year of publication, number and location of centers), study
design (type of study, sample size, inclusion and exclusion
criteria, length of follow-up, type and dosage of vitamin D
supplements) and patient population (age, gender, type
of immunosuppression, donor type, duration of renal-
replacement therapy, percentage of hemodialysis patients,
time since transplant, number of prior transplants and
cold ischemia time) will be included. These variables will
be extracted for all types of studies.
The continuous variables extracted include GFR (as
measured by inulin clearance), estimated GFR (eGFR;
estimated from serum creatinine) and proteinuria. Protein-
uria will be measured by 24-hour urine protein collection
or the albumin-to-creatinine ratio, depending on the
information that is available. For categorical variables,
the extracted outcomes will be acute rejection, delayed
graft function, graft loss and biopsy scores for interstitial
fibrosis and tubular atrophy.
Time since transplantation will be recorded for each of
the outcome variables. Time points will differ depending
on which follow-up intervals were selected by the study
author; this will be considered during data analysis. Out-
comes will be recorded on separate spreadsheets for stud-
ies assessing serum vitamin D levels and studies assessing
vitamin D supplementation (treatment group vs control).
Quality assessment
If there are eligible randomized controlled trials, quality
will be evaluated using the Cochrane Risk Assessment
Tool. Studies will be assessed on randomization, gener-
ation of allocation sequence, allocation concealment,
blinding and follow-up. We will evaluate observational
studies with the Newcastle–Ottawa Scale. The quality of
evidence across studies will be assessed for each outcome
using the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) approach. GRADE
considers the risk of bias, consistency of results across
studies, precision of the overall estimate across studies,
magnitude of effect and importance of the outcome [20].
The quality of evidence will be rated as high, moderate,
low or very low for each outcome.
Analysis plan
For all included studies, we will provide a detailed de-
scription of the results in both tables and text. We will
include data regarding study identification, study design
and patient population (as outlined above). For studies
assessing the effect of vitamin D supplementation, we
will compare outcomes (e.g. acute rejection) for patients
receiving vitamin D supplements to those for patients
not receiving supplements.
For studies that measure serum vitamin D concentra-
tion, we will compare outcomes in patients with vitamin
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D levels. As these definitions were not developed for the
renal transplant population, we will also examine serum
vitamin D as a continuous variable. We will pool treatment
effect estimates where possible using standard statistical
techniques. In the event that combining data across studies
is not feasible due to inadequate information or excessive
heterogeneity, we will use descriptive methods to present
data by outcome.
Our inclusion criteria do not specify time points at
which outcomes are measured (e.g. GFR at 12 months) to
avoid excluding potentially useful information; however,
we will account for timing during data analysis. We intend
to group all studies together initially and then perform
sensitivity analyses for different time points (e.g. GFR at
less than one year or greater than one year), if possible.
Discussion
In this systematic review, we will assess the impact of
serum vitamin D concentration and vitamin D supple-
mentation on renal transplant outcomes. While our meth-
odology is designed to minimize selection bias, we do
anticipate several limitations with this review: clinical
and methodological heterogeneity, the quality of existing
studies and the paucity of randomized controlled trials.
Therefore, we anticipate that we may not be able to
combine studies for a meta-analysis, but rather present
findings using descriptive methods.
Our primary outcome is the GFR determined by direct
measurement or estimation from serum creatinine con-
centrations. This outcome is subject to methodological
heterogeneity, as the GFR is unlikely to be measured at
the same time in all studies. We have not specified time
points as inclusion criteria due to the risk of eliminating
potentially relevant studies. Including studies with different
time points may complicate data extraction and analysis;
however, we feel it is important to increase the sensitivity of
our review. If there are sufficient studies at a certain time
point (e.g. 1-year post transplantation), we plan to pool the
data where appropriate.
Another source of heterogeneity is the use of vitamin
D compounds with different physiological mechanisms
(e.g. cholecalciferol vs calcitriol vs paricalcitol), which
may or may not have different effects on graft function.
Previous data suggest that calcitriol may have greater
parathyroid hormone (PTH)-lowering effects and a greater
risk of hypercalcemia than nutritional compounds [21,22].
There may also be important differences between pari-
calcitol, a selective vitamin D receptor agonist, and
the nonselective calcitriol regarding PTH-lowering,
risk of hypercalcemia and overall survival [23,24]. We
must consider that nutritional vitamin D and selective
and non-selective vitamin D receptor agonists may
affect transplant function differently, which may limitopportunities for pooling treatment effects. To maximize
the yield of our literature search, however, we will include
studies with all vitamin D formulations, including nutri-
tional compounds, receptor agonists and vitamin D
analogs. Including different formulations will increase
the comprehensiveness of our review and may allow us to
compare the effects of various vitamin D compounds.
Cross-sectional studies that compare serum vitamin D
concentration with transplant outcome may provide
important information; however, they also introduce
the possibility of reverse causation. It has been well
established that vitamin D levels decline with chronic
kidney disease. Thus, in a cross-sectional study showing
an association between low vitamin D concentration
and reduced GFR, one cannot confidently exclude the
possibility that reduced kidney function was the cause
of vitamin D deficiency, rather than the result. There-
fore, associations between serum vitamin D and GFR
must be interpreted with caution.
Lastly, our results may be confounded by our inability
to control for sun exposure and dietary vitamin D intake.
Neither can be measured accurately in the typical out-
patient setting. Studies that assess vitamin D supplemen-
tation without baseline serum concentrations are unlikely
to capture a patient’s vitamin D status completely. Meas-
uring baseline vitamin D concentrations will partially
reduce this bias, though incompletely due to ongoing
potential differences in vitamin D exposure via sunlight
and diet. Although we recognize this as a limitation, after a
renal transplant, patients are cautioned about sun exposure
secondary to concerns about skin cancer. If patients follow
this recommendation, differences in sun exposure should
be minimized. The impact of nutritional vitamin D intake
on serum vitamin D levels is unlikely to be significant.
In summary, our systematic review will provide insight
into the effects of vitamin D insufficiency and/or replace-
ment on renal transplant function. The results may have
an immediate impact on patient care and facilitate
guideline development for nutritional supplements for
renal transplant patients. The data will also serve as
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